Dexcom (NSDQ:DXCM) today shared results from two studies of continuous glucose monitors, including its next-generation G7 CGM. San Diego-based Dexcom presented the studies during the 14th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD). The first study, the Mobile study, published in JAMA, observed 175 ethnically and socioeconomically diverse adults (30 years old […]
Diabetes
Study shows CGMs better at controlling blood sugar in type 2 diabetes
Kaiser Permanente is touting a study demonstrating that using continuous glucose monitors offers better blood sugar control for patients with type 2 diabetes. The study found that patients with insulin-treated type 2 diabetes using continuous glucose monitors (CGMs) typically had better blood sugar control and fewer visits to the emergency room for hypoglycemia. The study […]
Medtronic touts real-world results for MiniMed 780G insulin pump
Medtronic (NYSE:MDT) today announced positive real-world outcomes for thousands of patients using the MiniMed 780G insulin pump system. Fridley, Minn.-based Medtronic’s MiniMed 780G system automates and personalized the delivery of basal insulin through adjustments every five minutes for 24 hours a day. It includes an advanced algorithm designed to automatically correct highs every five minutes […]
DarioHealth touts research on digital therapeutics for diabetes patients
DarioHealth (NSDQ:DRIO) announced today that recently published research supports its digital therapeutic platform for type 2 diabetes. New York-based DarioHealth published a new study through a letter to the editor in the Journal of Diabetes Science and Technology, according to a news release. The study observed participants using DarioHealth’s digital therapeutics for diabetes management, monitoring […]
Medtronic wins CE mark for smart insulin pen, Guardian 4 sensor
Medtronic (NYSE:MDT) announced today that it received CE mark approvals for its InPen smart insulin pen and its Guardian 4 sensor. Fridley, Minn.-based Medtronic’s new European approvals cover expanded functionality of the InPen for multiple daily injections (MDI), along with approval for the Guardian 4 sensor that requires no fingersticks for calibration or diabetes treatment […]
How Fractyl Health is ‘reversing’ type 2 diabetes to reduce or eliminate insulin injections
Fractyl Health CEO Harith Rajagopalan envisions a scenario in which those with type 2 diabetes don’t have to rely on insulin injections. Insulin has long been a staple of treatment for type 2 diabetes patients who need to manage their blood sugar levels, but Rajagopalan’s aim is to go beyond that temporary fix. Trained as […]
DarioHealth acquires PsyInnovations for $30M
DarioHealth announced that it entered into an agreement to acquire digital health company PsyInnovations for up to $30 million. PsyInnovations develops the wayForward behavioral digital health platform with AI-enabled screening to triage and navigate members to specific interventions, digital cognitive behavioral therapy (CBT), self-directed care, expert coaching and access to in-person and telehealth provider visits, according […]
FDA issues draft clinical trial guidelines for neurostim, other devices to treat diabetes
The FDA today issued a draft guidance with recommendations for clinical trials for certain devices intended for treating diabetes. Included in the guidance are recommendations for feasibility and early feasibility clinical studies for certain medical devices intended to therapeutically improve glycemic control in patients with type 2 diabetes mellitus, independent of medication delivery. Among the […]
Neurodon prepping IND application for type 1 diabetes treatment
Neurodon announced today that it initiated studies to prepare an FDA Investigational New Drug (IND) application for its type 1 diabetes treatment. Crown Point, Ind.-based Neurodon’s NDC-0009 novel molecule targets endoplasmic reticulum (ER) stress, a pathway triggered by factors arising from disease that features in type 2 and type 2 diabetes, as well as inflammation […]
Senseonics stock up on Street-beating Q1
Senseonics (NYSE:SENS) shares rose today on first-quarter results that beat the consensus forecast. The Germantown, Md.-based diabetes management technology developer posted losses of -$249.5 million, or -68¢ per share, on sales of $2.8 million for the three months ended March 31, 2021, registering a massive bottom-line slide from losses of -$42.6 million this time one […]